exRNAdisease

General Information

Database ID:

exR0081073

RNA Name:

SERF2

RNA Type:

mRNA

Chromosome:

chr15

Starnd:

Coordinate:

Start Site(bp):

43777087

End Site(bp):

43802589

External Links:

Disease Information

Disease Name:	Fragile X Syndrome
Disease Category:	Congenital, Hereditary, and Neonatal Diseases and Abnormalities
MeSH ID:	D005600
Type:	Diseases Category/Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Alias:	Fragile X Syndromes//Syndrome, Fragile X//Syndromes, Fragile X//Marker X Syndrome//Marker X Syndromes//Syndrome, Marker X//Syndromes, Marker X//Mental Retardation, X-Linked, Associated With Marxq28//X-Linked Mental Retardation and Macroorchidism//X Linked Mental Retardation and Macroorchidism//Fragile X Mental Retardation Syndrome//Martin-Bell Syndrome//Martin Bell Syndrome//Syndrome, Martin-Bell//Fra(X) Syndrome//FRAXE Syndrome//FRAXE Syndromes//Syndrome, FRAXE//Syndromes, FRAXE//Mental Retardation, X-Linked, Associated With Fragile Site Fraxe//Fragile X-F Mental Retardation Syndrome//Mar (X) Syndrome//FRAXA Syndrome//FRAXA Syndromes//Syndrome, FRAXA//Syndromes, FRAXA

Expression Detail

GEO ID:	GSE83556
Description:	Global transcriptome dysregulation in second trimester fetuses with FMR1 expansions
Experimental Design:	Disease vs Control
Case Disease Type:	Fragile X Syndrome
Case Disease SubType:	NA
Case Sample:	Fragile X Syndrome
Control Sample:	Normal
Number of Case:	22
Number of Control:	18
Number of Samples:	40

Regulatory Relationship

mRNA targets:

Gene Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AATF	chr17	36948954	37056871	+
ABCB4	chr7	87401697	87480435	-
AC005258.1	chr19	2269525	2341172	+
AC005943.1	chr19	1578339	1605445	-
AC023055.1	chr12	55757275	55827546	-
AC073896.1	chr12	56285916	56316059	-
AC099811.2	chr17	42119674	42154916	-
AC120057.2	chr17	7240427	7244635	-
ACLY	chr17	41866917	41930542	-
ACTB	chr7	5527148	5563784	-
ACTC1	chr15	34790230	34795549	-
ACTG1	chr17	81509971	81523847	-
ACTR8	chr3	53867066	53882152	-
ADA	chr20	44619522	44652233	-
ADD3	chr10	109996368	110135565	+
ADIPOR1	chr1	202940826	202958572	-
AGAP4	chr10	45825594	45853875	-
AHCY	chr20	34280268	34311802	-
AL049629.2	chr11	33698261	33722467	-
AL121753.1	chr20	35267885	35280043	-
AL136295.1	chr14	24189157	24213473	-
AL136295.4	chr14	24180395	24190416	-
AL139260.3	chr1	38864501	38881617	-
ALDH18A1	chr10	95605941	95656711	-
ALDH4A1	chr1	18871430	18902724	-

miRNA targets:

miRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
hsa-miR-31-5p	chr9	21512158	21512178	-
hsa-miR-296-3p	chr20	58817626	58817647	-
hsa-miR-423-5p	chr17	30117095	30117117	+

circRNA targets:

lncRNA targets:

lncRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AC005618.1	chr5	141326210	141329357	+
AC016876.2	chr17	7581964	7584086	-
AC126365.1	chr17	20788071	20789584	+
AL121603.2	chr14	34874343	34876459	+
AL132780.1	chr14	22929607	22956374	+

Display:

Experiment Detail

GEO ID:	GSE83556
Sample Source:	Amniotic Fluid
Source Fraction:	Supernatant
Platform:	GPL570
Method:	Microarray
Num of detected RNA Type:	1
Num of detected RNAs of this Type:	17063
Sample treatment protocol:	RNA was extracted from 5-15 mL amniotic fluid supernatant (centrifugation at 350g, 4C, 10, min).
RNA Extract protocol:	All samples were processed using the Qiagen Circulating Nucleic Acid kit with an on-column DNase digestion step to remove genomic DNA. The RNA was then purified and concentrated with the RNeasy MinElute Clean up kit and eluted in RNasefree water.
RNA library preparation protocol:	RNA was converted to cDNA and amplified using the Ovation Pico WTA kit V2 and then purified with the QIAquick PCR Purification kit. Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA)Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA).

Reference